Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We currently depend on Teva Pharmaceuticals Industries Ltd, as our single-source supplier of mitomycin API for Jelmyto, Zusduri, UGN-103 and UGN-104.”
FILING10-K0001437749-26-006234cik 0001668243
“In November 2019, we entered into a license agreement with Agenus, pursuant to which Agenus granted us an exclusive, worldwide (not including Argentina, Brazil, Chile, Colombia, Peru, Venezuela and their respective territories and possessions), royalty-bearing, sublicensable license under Agenus's intellectual property rights to develop, make, use, sell, import, and otherwise commercialize products incorporating a proprietary monoclonal antibody of Agenus known as AGEN1884 (zalifrelimab), an anti-CTLA-4 antagonist, for the treatment of cancers of the urinary tract via intravesical delivery.”
FILING10-K0001437749-26-006234cik 0001668243
“We currently rely on Cenexi-Laboratories Thissen s.a. for the bulk mitomycin contained in Jelmyto and Zusduri .”
FILING10-K0001437749-26-006234cik 0001668243
“On February 14, 2025 (the "Closing Date"), we entered into an asset purchase agreement (the "IconOVir Agreement") with IconOVir Bio, Inc. ("IconOVir"), pursuant to which we purchased and acquired certain assets of IconOVir (the "Transferred Assets"), including UGN-501 (formerly ICVB-1042) and certain contracts, intellectual property rights, regulatory applications, submissions and registrations, and data and other rights related thereto, and assumed certain liabilities and obligations of IconOVir arising under certain contracts of IconOVir acquired by us.”
FILING10-K0001437749-26-006234cik 0001668243
“We depend on Isotopia Molecular Imaging Ltd. as our single contracted suppliers for the hydrogel contained in Jelmyto and Zusduri .”
FILING10-K0001437749-26-006234cik 0001668243
“For example, in August 2020, we announced that the Phase 2 APOLLO trial of BOTOX/ RTGel for the treatment of overactive bladder, which was conducted by Allergan Pharmaceuticals Limited ("Allergan"), did not meet the primary endpoint.”
FILING10-K0001437749-26-006234cik 0001668243
Watchlist prices, news filtered to it, and its next report on your desk.
UroGen Pharma Ltd.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 41.78 · gapped above the open, then crossed back over prior close. High/low 42.90 at 6:15 am ET, 41.20 at 1:45 pm ET.
UroGen Pharma Ltd. has 6 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either UroGen Pharma Ltd.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of UroGen Pharma Ltd.. Customers appear here when UroGen Pharma Ltd. names them, or when a company names UroGen Pharma Ltd. as a supplier in its own annual report.
URGN (UroGen Pharma Ltd.) has 6 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: TEVA −0.87%, in healthcare.